ATSN-101治疗GUCY2D双等位基因突变所致Leber先天性黑矇的安全性与疗效:一项1/2期、多中心、开放标签、单侧剂量递增研究
这项1/2期多中心开放标签单侧剂量递增研究纳入15例GUCY2D双等位基因突变确诊的Leber先天性黑矇1型患者,单侧视网膜下注射ATSN-101。高剂量组治疗眼12个月暗适应FST平均变化20.3 dB(95%CI 6.6至34.0),未治疗眼1.1 dB(-3.7至5.9),p=0.012;BCVA改善p=0.10。ATSN-101耐受良好,无药物相关严重不良事件。
要点
- 高剂量组治疗眼12个月暗适应FST平均变化20.3 dB,未治疗眼1.1 dB,p=0.012。
- 共观察68例次治疗中出现的不良事件,其中56例次与手术操作相关。
- 6例高剂量组并完成MLMT的患者中3例治疗眼达到最高分。
核心结论
- ATSN-101治疗后12个月耐受良好,无药物相关严重不良事件。
- 接受高剂量的患者视网膜敏感性出现临床显著且持续的改善。
研究设计与样本
- 1/2期、多中心、开放标签、单侧剂量递增研究,纳入15例经基因确诊的GUCY2D双等位基因突变患者。
- 剂量递增阶段三个成人队列(各n=3)分别接受低剂量1.0×10^10 vg/眼、中剂量3.0×10^10 vg/眼和高剂量1.0×10^11 vg/眼。
- 剂量扩展阶段一个成人队列(n=3)和一个儿童队列(n=3)接受高剂量治疗。
- 主要终点为治疗中出现的不良事件发生率,次要终点包括全视野刺激试验和最佳矫正视力。
- 患者入组时间为2019年9月12日至2022年5月5日,报告12个月主要研究期数据。
主要发现
- 共观察68例次治疗中出现的不良事件,其中56例次与手术操作相关。
- 无与研究药物相关的严重治疗中出现的不良事件。
- 眼部炎症轻微,经类固醇治疗可逆。
- 高剂量组治疗眼12个月暗适应FST平均变化20.3 dB(95%CI 6.6至34.0),未治疗眼1.1 dB(-3.7至5.9),p=0.012;改善首次见于第28天并持续12个月(白色刺激)。
- BCVA也观察到适度改善(p=0.10);6例接受高剂量并完成MLMT的患者中3例治疗眼达到最高分。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Leber congenital amaurosis 1 (LCA1), caused by mutations in GUCY2D, is a rare inherited retinal disease that typically causes blindness in early childhood. The aim of this study was to evaluate the safety and preliminary efficacy of ascending doses of ATSN-101, a subretinal AAV5 gene therapy for LCA1. METHODS: 15 patients with genetically confirmed biallelic mutations in GUCY2D were included in this phase 1/2 study. All patients received unilateral subretinal injections of ATSN-101. In the dose-escalation phase, three adult cohorts (n=3 each) were treated with three ascending doses: 1·0 × 1010 vg/eye (low dose), 3·0 × 1010 vg/eye (middle dose), and 1·0 × 1011 vg/eye (high dose). In the dose-expansion phase, one adult cohort (n=3) and one paediatric cohort (n=3) were treated at the high dose. The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs), and secondary endpoints included full-field stimulus test (FST) and best-corrected visual acuity (BCVA). A multi-luminance mobility test (MLMT) was also done. Data through the 12-month main study period are reported. FINDINGS: Patients were enrolled between Sept 12, 2019, and May 5, 2022. A total of 68 TEAEs were observed, 56 of which were related to the surgical procedure. No serious TEAE was related to the study drug. Ocular inflammation was mild and reversible with steroid treatment. For patients who received the high dose, mean change in dark-adapted FST was 20·3 decibels (dB; 95% CI 6·6 to 34·0) for treated eyes and 1·1 dB (-3·7 to 5·9) for untreated eyes at month 12 (white stimulus); improvements were first observed at day 28 and persisted over 12 months (p=0·012). Modest improvements in BCVA were also observed (p=0·10). Three of six patients who received the high dose and did the MLMT achieved the maximum score in the treated eye. INTERPRETATION: ATSN-101 is well tolerated 12 months after treatment, with no drug-related serious adverse events. Clinically significant improvements in retinal sensitivity were sustained in patients receiving the high dose. FUNDING: Atsena Therapeutics.
引用
- Yang P, Pardon LP, Ho AC, et al. Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral dose escalation study. Lancet. 2024. PMID: 39244273. doi:10.1016/S0140-6736(24)01447-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。